Distribution of Antibodies in Colorectal Cancer Models
Author Information
Author(s): R.B. Pedley, G.M. Boxer, J.A. Boden, P.J. Southall, R.H.J. Begent, K.D. Bagshawe, J. Humm, F. Searle
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital
Hypothesis
The study investigates how the distribution and retention of radiolabelled antibodies in human colorectal cancer xenografts can inform microdosimetry for therapy.
Conclusion
The antibodies showed uneven distribution over time, suggesting that therapy may be more effective with isotopes that exploit late retention in necrotic areas.
Supporting Evidence
- The antibodies localise independently at low concentrations.
- Slow accumulation and retention predominantly in membranes of glands and necrotic areas suggest optimal therapy with specific isotopes.
- Calculations of dose to tumour may underestimate cytotoxicity to individual cells.
Takeaway
The study looked at how two types of antibodies spread in cancer cells in mice, finding that they don't spread evenly, which could affect treatment.
Methodology
Autoradiography was used to track the distribution of '251-labelled antibodies in nude mice with human colorectal cancer xenografts over 72 hours.
Limitations
The study may not fully represent human responses due to the use of mouse models.
Participant Demographics
Nude mice with two distinct human colorectal cancer xenografts (MAWI and TAF).
Want to read the original?
Access the complete publication on the publisher's website